

CODING AND BILLING SHEET

Beyfortus Product Codes

CPT^{®a} code **90380** or **90381** should be assigned on all claims for Beyfortus. These codes describe a 0.5-mL dose and a 1-mL dose of this pediatric, once per season, passive immunization for RSV^b. It is not necessary to use modifier-51 when reporting these codes. See the grid below for more information on billing these codes.

CPT Code	Code Description	Suggested Use
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	Bill 1 unit of 90380 when a 0.5-mL dose is provided.
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use	Bill 1 unit of 90381 when a 1-mL dose is provided. Bill 2 units of 90381 when a 2-mL dose is provided.

Source: 2023 Current Procedural Terminology - all code descriptions are as defined by the American Medical Association.

NEW Administration Codes effective October 6, 2023

The administration of Beyfortus is reported in addition to the product code. On October 6, 2023 CPT released 2 new codes to report the administration of Beyfortus, effective immediately. Report the administration service with code 96380 or 96381 based on if a physician or other qualified healthcare professional (QHCP) provided counseling on the same date as the administration of Beyfortus. Do not report immunization administration codes 90460–90461 or 90471–90472 for administering Beyfortus, as these codes are limited to the administration of vaccine and toxoid products. See the grid below for more information on which administration code to choose when billing for administration of Beyfortus.

Code	Code Description	Suggested Use
96380	Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional (Report 96380 for administration of respiratory syncytial virus, monoclonal antibody, seasonal dose [90380, 90381])	For the administration service, when counseling is performed by a provider who independently bills, such as a physician or other qualified health care professional, report 96380 with the Beyfortus product code 90380 or 90381. Bill 96380 when any size dose of Beyfortus is administered and the counseling requirement is met.
96381	Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection (Report 96381 for administration of respiratory syncytial virus, monoclonal antibody, seasonal dose [90380, 90381])	For the administration service, when counseling is not performed by a provider who independently bills, report 96381 with the Beyfortus product code 90380 or 90381. Bill 96381 when any size dose of Beyfortus is administered and the counseling requirement is not met.
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	For the administration service, until your payers update their systems to add the 2 new codes, you may need to report CPT 96372 with the Beyfortus product code 90380 or 90381. Check with your payers for their coding guidance. Bill 96372 when any size dose of Beyfortus is administered until your payers update their systems to add CPT codes 96380 and 96381.

Source: 2023 Current Procedural Terminology - all code descriptions are as defined by the American Medical Association. <https://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf>

Beyfortus is **indicated** for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Please see additional Important Safety Information continued on [page 2](#).

Administration Codes (continued)

During the transition to these new codes, payer policies may require reporting administration CPT code 96372 therapeutic, prophylactic, or diagnostic injection until their coverage policies and payment systems are ready to accept claims using CPT 96380 and 96381. CPT 96372 was the suggested code to use when billing for administration of Beyfortus (nirsevimab-alip) prior to the release of CPT 96380 and 96381. Contact the health plans that you work with to verify their coding requirements and to see when they will be ready to accept the new administration codes 96380 and 96381.

National Drug Codes (NDCs)

Some payers require an NDC in addition to the CPT code for the product. In such cases, it is important to format the NDC correctly or the claim will be denied and you will need to resubmit a corrected claim in order to be reconsidered for payment. Begin by determining if the payer requires the carton NDC or the unit-of-use NDC. On line 24A, place qualifier N4, the 11-digit NDC number (without hyphens), the Unit-of-Measure, and Units Dispensed. To convert the Beyfortus NDC to the required 11-digit format, add a leading zero in the middle section of numbers (ex. 49281-575-00 = 49281-**0**575-00). Unit-of-Measure, ML, is reported when the product is supplied in a liquid format. Units Dispensed is the actual decimal quantity administered. Continue to bill CPT code 90380 or 90381 and the appropriate administration code. Below is how to submit the NDCs for Beyfortus.

When the Payer Requires Carton NDC	When the Payer Requires Unit-of-Use NDC	Description
N449281057515 ML0.5	N449281057500 ML0.5	Carton of 5, 0.5-mL prefilled syringes (5x1)
N449281057415 ML1.0	N449281057488 ML1.0	Carton of 5, 1-mL prefilled syringes (5x1)
N449281057415 ML2.0	N449281057488 ML2.0	Carton of 5, 1-mL prefilled syringes (5x1)

Diagnosis Code (ICD-10-CM)^c

Below are the suggested diagnosis codes that may be appropriate when submitting claims for Beyfortus and its administration. The ICD-10 code should be linked to both the Beyfortus code 90380 or 90381, and the appropriate administration code. Assign the appropriate code based on review of the documentation in the medical record.

ICD-10-CM Code	Code Description	Suggested Use
Z29.11	Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV)	When a dose of RSV passive immunization is administered.
Applicable High-Risk Condition	Applicable High-Risk Condition Code Description	When a dose of RSV passive immunization is administered due to a high risk condition, add Z29.11 and the applicable ICD-10 code that describes each patient's high-risk condition.

Source: 2023 International Classification of Diseases, 10th Revision - Clinical Modification

Billing for Visits and an Immunization

If an immunization is the only service provided, a visit is not billed. When a separate and significant visit is provided along with an immunization, bill for the visit and the immunization services. When an immunization is administered at any type of visit, the modifier -25 may need to be attached to the evaluation and management code along with an ICD-10 which describes the reason for the visit to identify that it is separate and significantly different than other services billed. Check with your payers to confirm their requirements regarding the use of the -25 modifier.

IMPORTANT SAFETY INFORMATION [CONTINUED]

Warnings and Precautions

- **Hypersensitivity Including Anaphylaxis:** Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.

Please see additional Important Safety Information continued on [page 3](#).

Billing Examples

An infant is seen for a well visit and receives a 1-mL dose of Beyfortus. The physician counsels the parent on the passive immunization. The patient's plan is ready to accept the new administration codes and requires NDCs on claims.

21. DIAGNOSIS OR NATURE OF ILLNESS										22. MEDICARE RESUBMISSION									
1. <u>Z00.129</u>										Bill 1 unit of CPT code 90381 for a 1-mL dose of Beyfortus and link to the diagnosis code for the immunization, Z29.11.									
2. <u>Z29.11</u>																			
24. A N449281057415 ML1.0																			
DATE(S) OF SERVICE		To		Place of Service	Type of Service	PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)		DIAGNOSIS CODE	\$ CHARGES	DAYS OR UNITS	EPSDT Family Plan	EMG	COB	RESERVED FOR LOCAL USE	ACTION				
From	MM	DD	YY			MM	DD									YY	CPT/HCPCS	MODIFIER	
10	02	23	10	02	23	11	99391	25	1	1									
10	02	23	10	02	23	11	90381		2	1									
10	02	23	10	02	23	11	96380		2	1									

The ICD-10 code attached to the office visit must describe the reason for the visit and modifier-25 is attached to the visit code to show it is separate and significant from the immunization services.

Bill 1 unit of CPT code 96380 for administering Beyfortus because a QHCP counseled. Link to the diagnosis code Z29.11.

An infant is seen for a well visit and receives a 0.5-mL dose of Beyfortus. The registered nurse counsels the parent on the passive immunization. The patient's plan is ready to accept the new administration codes and requires NDCs on claims.

21. DIAGNOSIS OR NATURE OF ILLNESS										22. MEDICARE RESUBMISSION									
1. <u>Z00.129</u>										Bill 1 unit of CPT code 90380 for a 0.5-mL dose of Beyfortus and link to the diagnosis code for the immunization, Z29.11.									
2. <u>Z29.11</u>																			
24. A N449281057515 ML0.5																			
DATE(S) OF SERVICE		To		Place of Service	Type of Service	PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)		DIAGNOSIS CODE	\$ CHARGES	DAYS OR UNITS	EPSDT Family Plan	EMG	COB	RESERVED FOR LOCAL USE	ACTION				
From	MM	DD	YY			MM	DD									YY	CPT/HCPCS	MODIFIER	
10	05	23	10	05	23	11	99391	25	1	1									
10	05	23	10	05	23	11	90380		2	1									
10	05	23	10	05	23	11	96381		2	1									

The ICD-10 code attached to the office visit must describe the reason for the visit and modifier-25 is attached to the visit code.

Bill 1 unit of CPT code 96381 for administering Beyfortus because a QHCP did not counsel. Link to the diagnosis code for the immunization Z29.11.

Vaccines for Children (VFC) Billing

Be aware that many Medicaid plans stipulate which codes can be billed for administering immunizations available through the VFC program. Be sure to investigate the coding rules for your Medicaid plans, for this monoclonal antibody immunization, in case the required coding is different than the coding explained here.

CVX and MVX Codes

CVX and MVX codes are used to populate immunization registries. The CVX code indicates which product was used and the MVX code indicates the manufacturer of the product. When a MVX (manufacturer) code is paired with a CVX (product administered) code, the specific trade named product can be identified. The CVX codes for Beyfortus are **306** for a 0.5-mL dose and **307** for a 1-mL dose. The MVX for Sanofi is **PMC^d**.

IMPORTANT SAFETY INFORMATION [CONTINUED]

Warnings and Precautions

- Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see Prescribing Information for Beyfortus.

Do you have questions on coverage or payment for Sanofi products? Contact a Sanofi Reimbursement Specialist (RS). Call 1-800-VACCINE (1-800-822-2463) and choose the prompt for the RS.

Visit www.crackingthecodestraining.com for on-demand coding and billing videos and resources for Sanofi products.

Visit the Coding Education and Reimbursement Support Page on VaccineShop.com[®] for additional coding resources for Sanofi products.

^a CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association; ^b RSV = Respiratory syncytial virus; ^c ICD-10 = International Classification of Diseases, 10th Revision; ^d PMC = Pasteur Merieux Connaught.

The information contained in this Coding and Billing Sheet is provided for informational purposes only. Every reasonable effort has been made to verify the accuracy of the information; however, this quick reference is not intended to provide specific guidance on how to utilize, code, bill, or charge for any product or service. Health care providers should make the ultimate decision as to when to use a specific product based on clinical appropriateness for a particular patient. Third-party payment for medical products and services is affected by numerous factors and Sanofi Inc. cannot guarantee success in obtaining insurance payments.